Pfizer faces 2027 patent cliff as new drugs lag
Alpha Vantage · Trefis · · AI-summarised by FinFlash
Pfizer stock yields 5.8% as the company works to replace older drugs facing patent expirations. Management flagged loss of exclusivity for Ibrance, Xtandi and Eliquis as key 2027 factors, raising concern that patent losses could outpace new drug growth. Sales are holding steady and the dividend appears covered by free cash flow.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.